Dublin, Jan. 21, 2025 (GLOBE NEWSWIRE) -- The "United States Anesthesia Drugs Market by Type by General Inhalation by General Intravenous by Local, and Company Analysis 2025 to 2033" report has been added to ResearchAndMarkets.com's offering.
The United States anesthesia drugs market is expected to reach from US$ 2.61 billion in 2024 to US$ 3.67 billion in 2033 with a compound annual growth rate of 3.86% from 2025 to 2033. More surgeries, development in technologies of anesthesia, and enhanced safety and comfort for the patient are factors behind such a growth.
Anesthesia drugs are also commonly used in various settings within the United States' healthcare systems. These settings include hospitals, outpatient surgical centers, dental offices, and many more. Their applications include surgery, diagnostic procedures, labor and delivery, and pain management. Drugs include propofol, sevoflurane, and lidocaine; the type of anesthesia depends upon the drugs. In the US, with advanced medical technologies, there is emphasis given to the safety, efficacy, and recovery time that go along with the drugs during anesthesia.
Increasing Surgical Procedure
The high rate of surgical procedures in the U.S. contributes significantly to the growth of the anesthesia drugs market. In the United States, every year, about 15 million people undergo surgery. These include an increase in surgeries that are elective or emergency-type surgeries, especially orthopedic, cardiovascular, or cosmetic surgeries, which occur due to a growing proportion of older-aged populations, thus raising a demand in anesthesia drugs to maintain painlessness and safety among patients receiving such procedures.
Additionally, sedation anesthesia-based minimally invasive surgeries are increasingly being performed, thus increasing the demand for specialized drugs in anesthesia. For example, in September 2023, the American Society of Aesthetic Plastic Surgeons reported that 26.2 million surgical procedures are available in the U.S.
Anesthesia Drug Formulations Development
The growth of the market is also driven by the development of anesthesia drug formulations. Healthcare providers increasingly prefer new and improved anesthesia agents that provide faster recovery times, fewer side effects, and better patient outcomes. Drugs such as propofol and sevoflurane have gained popularity due to their efficiency and safety profiles.
Additionally, innovations in local anesthetics for targeted pain management are expanding their use in outpatient surgeries and procedures. These advancements lead to greater demand for modern anesthesia drugs for better patient experiences and clinical results. For example, on April 2024, Baxter launched Ropivacaine Hydrochloride Injection, USP, extending its pharmaceutical portfolio in the U.S. This prefilled, single-dose infusion bag is indicated for administration of local or regional anesthesia during surgery and for relief of acute pain in adults, thereby improving product line and competitive position.
Increasing Emphasis on Patient Safety and Comfort
As patient safety and comfort become more prioritized in medical care, the demand for safer and more effective anesthesia drugs is increasing. Healthcare providers focus on minimizing adverse effects such as postoperative nausea, dizziness, and prolonged recovery times. Anesthesia drugs that offer better control over anesthesia depth, faster onset, and quicker recovery are highly sought. Patient-centered care initiatives in the U.S. have been pushing for individualized anesthesia approaches, hence the development and adoption of drugs that would provide optimal safety while ensuring patient comfort during and after procedures.
Government Policy
Government initiatives and health reforms play a significant role in defining the U.S. market for general anesthesia drugs. A great deal of investments from the federal government has been into health infrastructure and funding surgical procedures, which increased demand for anesthesia. Various types of surgical procedures covered by Medicare and Medicaid increase surgeries that require general anesthesia and subsequently increase the demand for the general anesthesia drugs.
This area of research emphasizes improving surgery outcome and patient safety, stimulating advanced anesthesia techniques and pharmaceutical products. The current innovations relate to the creation of safe, innovative, and user-friendly anesthetic delivery devices and agents. Modern anesthesia drugs provide a better-controlled effect duration and depth to assure quick recovery time and maximal safety for the patient.
Healthcare reforms, government initiatives, and technological advancements are all crucial for the growth of the general anesthesia drugs market in the United States. Ongoing concern for patient safety and surgery effectiveness promotes the adoption of the latest drugs and anesthesia practices.
Regulatory bodies, especially the U.S. Food and Drug Administration (FDA), play a crucial role in the pharmaceutical industry, particularly anesthetics. The FDA's rigorous approval process ensures that only safe and effective anesthetic drugs are available. These regulatory guidelines influence various aspects of drug development, including labeling, dosage recommendations, and clinical trial requirements, all essential for the responsible application of anesthetic agents.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 120 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value (USD) in 2024 | $2.61 Billion |
| Forecasted Market Value (USD) by 2033 | $3.67 Billion |
| Compound Annual Growth Rate | 3.8% |
| Regions Covered | United States |
Company Analysis:
- Baxter International Inc
- Abbvie
- Medtronic Plc
- Draegerwerk AG
- Koninklijke Philips NV
- Abbott Laboratories
Key Topics Covered:
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. United States Anesthesia Drugs Market
6. Share Analysis
6.1 Anesthesia Drugs
6.2 General Inhalation Anesthesia Drugs Market
6.3 General Intravenous Anesthesia Drugs
6.4 Local Anesthesia Drugs
7. Types
7.1 General Inhalation
7.2 General Intravenous
7.3 Local
8. General Inhalation
8.1 Sevoflurane
8.2 Desflurane
8.3 Isoflurane
8.4 Others
9. General Intravenous
9.1 Propofol
9.2 Etomidate
9.3 Ketamine
9.4 Barbiturates
10. Local Anesthesia Drugs Market
10.1 Bupivacaine
10.2 Ropivacaine
10.3 Lidocaine
10.4 Chloroprocaine
10.5 Prilocaine
10.6 Benzocaine
10.7 Other local anesthetics
11. Merger & Acquisition (M&A)
12. Reimbursement Policy
12.1 Private Health Insurance Providers
12.1.1 Aetna International
12.1.2 Coventry Health Care
12.1.3 Anthem Blue Cross and Blue Shield
12.1.4 Blue Cross and Blue Shield of Texas
12.1.5 United Healthcare
12.2 Public Health Insurance Providers
12.2.1 Medicare
12.2.2 MDWise
13. Porter's Five Forces
14. SWOT Analysis
15. Key Players Analysis
For more information about this report visit https://www.researchandmarkets.com/r/lkmlbg
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
